Cardiodynamics Restructures Operations, Aspires To Return Of Profitability
This article was originally published in The Gray Sheet
Executive Summary
Cardiodynamics is considering partnering or merging with another non-invasive cardiovascular diagnostics firm to improve its distribution presence in the physician office market
You may also be interested in...
NCD opened for CardioDynamics
Firm hopes CMS will expand coverage of its thoratic electrical bioimpedance (TEB) devices for the management of all patients with hypertension. Coverage for the management of drug-resistant hypertension, defined by non-response to three or more medications, is at the discretion of local contractors, while other forms of hypertension are non-covered. CardioDynamics cites recent data from its multi-centered, randomized CONTROL trial as evidence that its BioZ impedance cardiography technology leads to greater reduction in blood pressure than standard care (1"The Gray Sheet" July 4, 2005, p. 15). An initial comment period on the decision ends March 30, with a proposed decision due by Aug. 28...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”